The voice of the ASEAN people

INSIDE·ASEAN

Connecting ASEAN with the World

Thailand

SeaX Ventures Invests in Skribe Medical: A New Era for Cardio-Oncology in Southeast Asia

The Thai venture capital firm backs Skribe Medical to enhance cardiac monitoring for cancer patients, aiming to streamline treatment processes in Thailand and beyond.

By Varut "Zack" Techawong15 November 20262 min read
SeaX Ventures Invests in Skribe Medical: A New Era for Cardio-Oncology in Southeast Asia

Bangkok-based SeaX Ventures has announced a $1.65 million investment in Skribe Medical, a U.S. startup specializing in wearable cardiac monitoring technology for cancer patients. This funding is expected to bolster Skribe's efforts to enhance cardiac assessments, particularly in the context of oncology treatments, which often face delays due to traditional monitoring methods.

Skribe Medical's innovative platform utilizes a multi-sensor adhesive patch designed to evaluate left ventricular ejection fraction (LVEF) — a critical measure of heart function — in a matter of minutes. This approach aims to reduce the bottlenecks associated with conventional echocardiograms, which require separate appointments and can postpone necessary cancer treatments. According to Skribe, timely cardiac assessments can decrease five-year mortality rates by 25% for cancer patients, highlighting the potential impact of their technology.

“Timely cardiac assessments can decrease five-year mortality rates by 25% for cancer patients.”Skribe Medical

As part of the investment, SeaX Ventures has facilitated collaborations with hospitals in Southeast Asia, helping to recruit over 100 patients for Skribe's ongoing NOECHO study. This study compares Skribe's wearable technology against traditional echocardiography across multiple sites, including one in Southeast Asia, as part of a broader effort to validate the effectiveness of their monitoring system.

“The investment reflects a growing interest in the intersection of wearable technology and healthcare.”Analysts

Ryan Neely, CEO of Skribe Medical, noted that the company's technology not only aims to streamline cardiac monitoring during oncology visits but also has the potential for home monitoring in the future. The company’s Aurora system has been selected for the FDA's READI-Home Innovation Challenge, which seeks to reduce hospital readmissions through the use of home-use devices. This participation is expected to provide early regulatory feedback, although it does not equate to marketing authorization.

Analysts suggest that the investment from SeaX Ventures reflects a growing interest in the intersection of wearable technology and healthcare, particularly in the oncology sector. However, some caution remains regarding the need for stronger clinical validation of wearable devices compared to established methods like echocardiography. As the healthcare landscape in Southeast Asia evolves, innovations like Skribe's may play a crucial role in enhancing patient care and treatment efficiency.